webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

N3-Aca-Aca-OH

  CAS No.: 866363-71-5   Cat No.: BADC-01792 4.5  

N3-Aca-Aca-OH is a bifunctional azide-containing ADC linker precursor designed for modular assembly of antibody-drug conjugates. It facilitates precise and stable payload attachment, improving therapeutic index in cancer treatment. Keywords: ADC linker, azide linker, bifunctional linker, drug conjugation.

N3-Aca-Aca-OH

Structure of 866363-71-5

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C12H22N4O3
Molecular Weight
270.33

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
6-[(6-Azido-1-oxohexyl)amino]hexanoic acid
IUPAC Name
6-(6-azidohexanoylamino)hexanoic acid
Canonical SMILES
C(CCC(=O)O)CCNC(=O)CCCCCN=[N+]=[N-]
InChI
InChI=1S/C12H22N4O3/c13-16-15-10-6-1-3-7-11(17)14-9-5-2-4-8-12(18)19/h1-10H2,(H,14,17)(H,18,19)
InChIKey
AEPIYQTVXFLWBW-UHFFFAOYSA-N

N3-Aca-Aca-OH, a versatile small molecule with immense potential in various bioscience applications, plays a pivotal role in peptide synthesis, protease inhibition, drug development, and diagnostics.

Peptide Synthesis: Acting as a fundamental building block in peptide synthesis, N3-Aca-Aca-OH is indispensable for constructing complex peptide chains using solid-phase techniques. Its unique chemical properties facilitate crucial coupling reactions required for tailoring peptides with precise sequences tailored for therapeutic and biochemical studies.

Protease Inhibition: Embracing its role as a protease inhibitor, N3-Aca-Aca-OH emerges as a key player in biochemical research, binding to specific classes of proteases and disrupting their active sites. This mechanism sheds light on protease function and regulation, particularly in diseases marked by protease dysregulation.

Drug Development: Spearheading innovations in pharmaceutical research, N3-Aca-Aca-OH contributes significantly to the design and refinement of novel therapeutics. Its intricate structure enables the modification of lead compounds to enhance pharmacokinetics and bioavailability, amplifying the efficacy of drugs aimed at combatting diverse diseases like cancer and infectious ailments.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Boc-PEG4-Val-Cit-PAB-OH | NHS-SS-Ph | 4-(4-Acetyl-phenoxy)-butyric acid | Alkyne-Val-Cit-PAB-PNP | (2R,10S)-10-Benzyl-2-cyclopropyl-23-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6,9,12,15,18-pentaoxo-3-oxa-5,8,11,14,17-pentaazatricosanoic acid | Fmoc-PEG4-Val-Cit-PAB-OH | Tubulysin B | MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA | N3-L-Dab(Fmoc)-OH | DACN(Tos,Suc-OH) | N3-Aca-Aca-OH
Send Inquiry
Verification code
Inquiry Basket